The group's principle activities include discovering, developing and commercializing novel drugs in infectious disease, inflammation and oncology. The group assembled a promising pipeline of clinical and preclinical product candidates for the treatment of respiratory tract infections, human immunodeficiency virus, acute respiratory distress syndrome and cancer. The group operates from United States.
